Psoriatic Disease
Primary Care Physician Guide to Psoriatic Disease
Phototherapy for Psoriasis
Topical Therapy for Psoriasis
Epidemiology and Classification of Psoriasis
Genetics and Pathogenesis of Psoriasis
Biologic Therapy for Psoriasis
Guselkumab brings active psoriatic arthritis into ‘stringent’ control through 2 years
Guselkumab for psoriatic arthritis led to major improvements in joint disease activity, complete skin clearance and other “stringent” endpoints that were maintained through 2 years, according to data published in Clinical Rheumatology.
Bimekizumab results in rapid, sustained improvements to PsA patient reported outcomes
Bimekizumab treatment for psoriatic arthritis demonstrated rapid, clinically meaningful improvements to patient reported outcomes that were sustained up to 1 year, according to data published in Rheumatology.
FDA approves Rinvoq for JIA, psoriatic arthritis in children aged 2 years and older
The FDA has expanded the indication of Rinvoq to include active, polyarticular juvenile idiopathic arthritis and psoriatic arthritis in children aged 2 years and older, according to an AbbVie press release.
Stress may be associated with increased risk of psoriasis among men
Low stress resilience in men may be linked to an increased risk for developing psoriasis or psoriatic arthritis, according to a study.